Royalty Pharma Plc (RPRX) Stock Price & Analysis
Royalty Pharma Plc (RPRX) rose 1.40% to USD 55.63 as of June 9, 2026 at 23:39 UTC, according to Nexqual real-time market data.
RPRX last closed at USD 54.86; the session ranged USD 54.35–55.82 on volume of 3,671,442 shares. Market capitalization is $32.03B, with a 52-week range of USD 33.4–56.5 (NMS). Source: Nexqual, June 9, 2026 at 23:39 UTC.
Key Statistics (as of June 9, 2026 at 23:39 UTC)
| Price | USD 55.63 |
|---|---|
| Change | ▲ 1.40% (up) |
| Previous Close | USD 54.86 |
| Open | USD 55.33 |
| Day Range | USD 54.35 – 55.82 |
| 52-Week Range | USD 33.4 – 56.5 |
| Volume | 3,671,442 shares |
| Market Cap | $32.03B |
| Exchange | NMS |
Technical Analysis (RPRX)
Nexqual's technical model rates RPRX "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 9, 2026 at 23:39 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 63.63 (neutral) |
| vs SMA50 | Above (USD 51.09) |
| MACD | 1.31 (positive) |
Analyst Ratings (RPRX)
Wall Street analysts rate RPRX "Strong Buy" based on 8 analysts, with a mean price target of USD 59.25 (range USD 46–66), per Nexqual as of June 9, 2026 at 23:39 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 59.25 |
| High Target | USD 66 |
| Low Target | USD 46 |
| Buy / Hold / Sell | 9 / 1 / 0 |
Earnings (RPRX)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 1.27 |
| Revenue Estimate | $805.07M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.3 vs est 1.18 ▲ beat |
| 2025-12-31 | USD 1.47 vs est 1.33 ▲ beat |
| 2025-09-30 | USD 1.17 vs est 1.04 ▲ beat |
| 2025-06-30 | USD 1.14 vs est 1.03 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:39 UTC.
Financials & Fundamentals (RPRX)
| Total Revenue | $2.44B |
|---|---|
| Revenue Growth (YoY) | +11.00% |
| Gross Margin | +115.00% |
| Operating Margin | +100.30% |
| Profit Margin | +33.86% |
| ROE | +13.77% |
| Debt / Equity | 90.32 |
| Current Ratio | 2.66 |
| Total Cash | $608.29M |
| Total Debt | $8.97B |
| Free Cash Flow | $-980.30M |
Source: Nexqual, June 9, 2026 at 23:39 UTC.
Financial Health Score (RPRX)
Nexqual rates Royalty Pharma Plc's overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:39 UTC.
| Growth | Strong — Revenue +16% YoY (annual) |
|---|---|
| Profitability | Strong — Operating margin 100% |
| Balance Sheet | Mixed — $608M cash vs $8.97B debt |
| Cash Flow | Weak — FCF negative: -$980M, burning cash |
| Efficiency | Mixed — ROE 14%, ROA 5.5% |
Ownership (RPRX)
| Insider Ownership | +7.16% |
|---|---|
| Institutional Ownership | +85.81% |
| Shares Outstanding | 443.27M |
| Float | 410.36M |
| Short % of Float | +2.90% |
Source: Nexqual, June 9, 2026 at 23:39 UTC.
Leadership (RPRX)
Royalty Pharma Plc is led by Pablo Legorreta (age 62), Founder, Chairman of the Board & CEO, per Nexqual as of June 9, 2026 at 23:39 UTC.
| Founder, Chairman of the Board & CEO | Pablo Legorreta (age 62) |
|---|---|
| Executive VP & CFO | Terrance P. Coyne |
| Chairman of Partnering & Investments | Christopher Hite (age 58) |
| Executive Vice President of Research & Investments | Marshall Jonathan Urist (age 49) |
| Senior VP & Chief Technology Officer | Eric Cornelius Schneider |
Major Backers & Investors (RPRX)
Notable institutional backers of Royalty Pharma Plc include Morgan Stanley, Capital International Investors, FMR, LLC, according to Nexqual as of June 9, 2026 at 23:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 11.01% |
| Capital International Investors | 7.9% |
| FMR, LLC | 5.67% |
| NEW PERSPECTIVE FUND | 4.43% |
| Baillie Gifford | 3.64% |
| Swedbank AB | 2.61% |
| Capital Income Builder | 1.94% |
| Capital Group | 1.81% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.84% |
| State Street | 2.48% |
Source: Nexqual, June 9, 2026 at 23:39 UTC.
From Royalty Pharma Plc's Latest SEC 10-K Filing (filed 2026-02-11)
Key Strengths & Strategy (as disclosed to the SEC)
- Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
- Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
- The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GTM | ZoomInfo Technologies Inc. | USD 2.77 | ▼ 7.05% |
| NCNO | nCino, Inc. | USD 15.52 | ▲ 4.02% |
| CYTK | Cytokinetics, Incorporated | USD 68.45 | ▼ 4.24% |
| GDRX | GoodRx Holdings, Inc. | USD 2.65 | ▲ 0% |
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 297.69 | ▼ 1.77% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:39 UTC. This page is informational and not investment advice.